Progress of transcatheter heart valve intervention_West China Medical Journal

Authors：

ZHAO Zhengang , CHEN Fei ,  CHEN Mao

Department of Cardiology, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, P. R. China;

Corresponding author：

CHEN Mao, Email: hmaochen@vip.sina.com

Keywords：

Heart valve disease; Transcatheter valve intervention; Antithrombotic therapy; Progress

DOI：

10.7507/1002-0179.202004188

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

At present, interventional therapy for structural heart disease is in a period of vigorous development. Among them, transcatheter aortic valve replacement, as a representative of the interventional treatment of heart valve disease, has made rapid progress, which is a bright spot in the field of cardiovascular disease. The future development of transcatheter tricuspid valve repair/replacement is also promising. With the availability of important clinical evidence, the indications of transcatheter aortic valve replacement have been extended to the full risk range of severe aortic stenosis. More and more data showed that transcatheter mitral and tricuspid valve interventions could effectively alleviate patients’ symptoms and improve their prognosis. Transcatheter valve interventions have developed rapidly and have made tremendous progress in China. This article will review and interpret the important progress in the field of transcatheter valve interventions.

Citation： ZHAO Zhengang, CHEN Fei, CHEN Mao. Progress of transcatheter heart valve intervention. West China Medical Journal, 2020, 35(4): 401-405. doi: 10.7507/1002-0179.202004188 Copy

1.	Nkomo VT, Gardin JM, Skelton TN, et al. Burden of valvular heart diseases: a population-based study. Lancet, 2006, 368(9540): 1005-1011.
2.	Mack MJ, Leon MB, Thourani VH, et al. Transcatheter aortic-valve replacement with a balloon-expandable valve in low-risk patients. N Engl J Med, 2019, 380(18): 1695-1705.
3.	Popma JJ, Deeb GM, Yakubov SJ, et al. Transcatheter aortic-valve replacement with a self-expanding valve in low-risk patients. N Engl J Med, 2019, 380(18): 1706-1715.
4.	Mack MJ. Two-year clinical and echocardiographic outcomes from the PARTNER 3 low-risk randomized trial. (2020-03-29)[2020-04-16]. https://www.crtonline.org/presentation-detail/two-year-clinical-echocardiographic-outcomes-from-.
5.	Yoon SH, Bleiziffer S, De Backer O, et al. Outcomes in transcatheter aortic valve replacement for bicuspid versus tricuspid aortic valve stenosis. J Am Coll Cardiol, 2017, 69(21): 2579-2589.
6.	Makkar RR, Fontana G, Jilaihawi H, et al. Possible subclinical leaflet thrombosis in bioprosthetic aortic valves. N Engl J Med, 2015, 373(21): 2015-2024.
7.	Chakravarty T, Søndergaard L, Friedman J, et al. Subclinical leaflet thrombosis in surgical and transcatheter bioprosthetic aortic valves: an observational study. Lancet, 2017, 389(10087): 2383-2392.
8.	Nishimura RA, Otto CM, Bonow RO, et al. 2017 AHA/ACC focused update of the 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines. J Am Coll Cardiol, 2017, 70(2): 252-289.
9.	Dangas GD, Tijssen JGP, Wöhrle J, et al. A controlled trial of rivaroxaban after transcatheter aortic valve replacement. N Engl J Med, 2020, 382(2): 120-129.
10.	De Backer O, Dangas GD, Jilaihawi H, et al. Reduced leaflet motion after transcatheter aortic-valve replacement. N Engl J Med, 2020, 382(2): 130-139.
11.	Stone GW, Lindenfeld J, Abraham WT, et al. Transcatheter mitral-valve repair in patients with heart failure. N Engl J Med, 2018, 379(24): 2307-2318.
12.	Mack MJ. COAPT: 3-year outcomes from a randomized trial of the mitraclip in patients with heart failure and severe secondary mitral regurgitation. (2019-09-28)[2020-04-16]. https://www.tctmd.com/slide/coapt-3-year-outcomes-randomized-trial-mitraclip-patients-heart-failure-and-severe-secondary.
13.	Obadia JF, Messika-Zeitoun D, Leurent G, et al. Percutaneous repair or medical treatment for secondary mitral regurgitation. N Engl J Med, 2018, 379(24): 2297-2306.
14.	EI Sabbagh A, Reddy YNV, Nishimura RA. Mitral valve regurgitation in the contemporary era: insights into diagnosis, management, and future directions. JACC Cardiovasc Imaging, 2018, 11(4): 628-643.
15.	Sorajja P, Moat N, Badhwar V, et al. Initial feasibility study of a new transcatheter mitral prosthesis: the first 100 patients. J Am Coll Cardiol, 2019, 73(11): 1250-1260.
16.	Ailawadi G. Tendyne: attributes, challenges, and clinical data (SUMMIT). (2019-06-14)[2020-04-16]. https://www.tctmd.com/slide/tendyne-attributes-challenges-and-clinical-data-summit.
17.	Bapat V, Rajagopal V, Meduri C, et al. Early experience with new transcatheter mitral valve replacement. J Am Coll Cardiol, 2018, 71(1): 12-21.
18.	Leon MB. Intrepid: attributes, challenges, and clinical data (APOLLO). (2019-06-14)[2020-04-16]. https://www.tctmd.com/slide/tendyne-attributes-challenges-and-clinical-data-summit.
19.	Taramasso M, Hahn RT, Alessandrini H, et al. The International Multicenter TriValve Registry: which patients are undergoing transcatheter tricuspid repair?. JACC Cardiovasc Interv, 2017, 10(19): 1982-1990.
20.	Taramasso M, Benfari G, van der Bijl P, et al. Transcatheter versus medical treatment of patients with symptomatic severe tricuspid regurgitation. J Am Coll Cardiol, 2019, 74(24): 2998-3008.
21.	Taramasso M, Alessandrini H, Latib A, et al. Outcomes after current transcatheter tricuspid valve intervention: mid-term results from the international trivalve registry. JACC Cardiovasc Interv, 2019, 12(2): 155-165.
22.	Giannini F, Baldetti L, Gallone G, et al. Transcatheter valve replacement in Asia Pacific: current practice and perspectives. J Am Coll Cardiol, 2018, 72(24): 3189-3199.
23.	Wang S, Meng X, Luo Z, et al. Transapical beating-heart mitral valve repair using a novel artificial chordae implantation system. Ann Thorac Surg, 2018, 106(5): e265-e267.
24.	Pan W, Zhou D, Wu Y, et al. First-in-human results of a novel user-friendly transcatheter edge-to-edge mitral valve repair device. JACC Cardiovasc Interv, 2019, 12(23): 2441-2443.
25.	Cao P. A new, non-radial force transcatheter tricuspid valve replacement (LuX Medical). (2019-09-26)[2020-04-16]. https://www.tctmd.com/slide/new-non-radial-force-transcatheter-tricuspid-valve-replacement-lux-medical.

1. Nkomo VT, Gardin JM, Skelton TN, et al. Burden of valvular heart diseases: a population-based study. Lancet, 2006, 368(9540): 1005-1011.
2. Mack MJ, Leon MB, Thourani VH, et al. Transcatheter aortic-valve replacement with a balloon-expandable valve in low-risk patients. N Engl J Med, 2019, 380(18): 1695-1705.
3. Popma JJ, Deeb GM, Yakubov SJ, et al. Transcatheter aortic-valve replacement with a self-expanding valve in low-risk patients. N Engl J Med, 2019, 380(18): 1706-1715.
4. Mack MJ. Two-year clinical and echocardiographic outcomes from the PARTNER 3 low-risk randomized trial. (2020-03-29)[2020-04-16]. https://www.crtonline.org/presentation-detail/two-year-clinical-echocardiographic-outcomes-from-.
5. Yoon SH, Bleiziffer S, De Backer O, et al. Outcomes in transcatheter aortic valve replacement for bicuspid versus tricuspid aortic valve stenosis. J Am Coll Cardiol, 2017, 69(21): 2579-2589.
6. Makkar RR, Fontana G, Jilaihawi H, et al. Possible subclinical leaflet thrombosis in bioprosthetic aortic valves. N Engl J Med, 2015, 373(21): 2015-2024.
7. Chakravarty T, Søndergaard L, Friedman J, et al. Subclinical leaflet thrombosis in surgical and transcatheter bioprosthetic aortic valves: an observational study. Lancet, 2017, 389(10087): 2383-2392.
8. Nishimura RA, Otto CM, Bonow RO, et al. 2017 AHA/ACC focused update of the 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines. J Am Coll Cardiol, 2017, 70(2): 252-289.
9. Dangas GD, Tijssen JGP, Wöhrle J, et al. A controlled trial of rivaroxaban after transcatheter aortic valve replacement. N Engl J Med, 2020, 382(2): 120-129.
10. De Backer O, Dangas GD, Jilaihawi H, et al. Reduced leaflet motion after transcatheter aortic-valve replacement. N Engl J Med, 2020, 382(2): 130-139.
11. Stone GW, Lindenfeld J, Abraham WT, et al. Transcatheter mitral-valve repair in patients with heart failure. N Engl J Med, 2018, 379(24): 2307-2318.
12. Mack MJ. COAPT: 3-year outcomes from a randomized trial of the mitraclip in patients with heart failure and severe secondary mitral regurgitation. (2019-09-28)[2020-04-16]. https://www.tctmd.com/slide/coapt-3-year-outcomes-randomized-trial-mitraclip-patients-heart-failure-and-severe-secondary.
13. Obadia JF, Messika-Zeitoun D, Leurent G, et al. Percutaneous repair or medical treatment for secondary mitral regurgitation. N Engl J Med, 2018, 379(24): 2297-2306.
14. EI Sabbagh A, Reddy YNV, Nishimura RA. Mitral valve regurgitation in the contemporary era: insights into diagnosis, management, and future directions. JACC Cardiovasc Imaging, 2018, 11(4): 628-643.
15. Sorajja P, Moat N, Badhwar V, et al. Initial feasibility study of a new transcatheter mitral prosthesis: the first 100 patients. J Am Coll Cardiol, 2019, 73(11): 1250-1260.
16. Ailawadi G. Tendyne: attributes, challenges, and clinical data (SUMMIT). (2019-06-14)[2020-04-16]. https://www.tctmd.com/slide/tendyne-attributes-challenges-and-clinical-data-summit.
17. Bapat V, Rajagopal V, Meduri C, et al. Early experience with new transcatheter mitral valve replacement. J Am Coll Cardiol, 2018, 71(1): 12-21.
18. Leon MB. Intrepid: attributes, challenges, and clinical data (APOLLO). (2019-06-14)[2020-04-16]. https://www.tctmd.com/slide/tendyne-attributes-challenges-and-clinical-data-summit.
19. Taramasso M, Hahn RT, Alessandrini H, et al. The International Multicenter TriValve Registry: which patients are undergoing transcatheter tricuspid repair?. JACC Cardiovasc Interv, 2017, 10(19): 1982-1990.
20. Taramasso M, Benfari G, van der Bijl P, et al. Transcatheter versus medical treatment of patients with symptomatic severe tricuspid regurgitation. J Am Coll Cardiol, 2019, 74(24): 2998-3008.
21. Taramasso M, Alessandrini H, Latib A, et al. Outcomes after current transcatheter tricuspid valve intervention: mid-term results from the international trivalve registry. JACC Cardiovasc Interv, 2019, 12(2): 155-165.
22. Giannini F, Baldetti L, Gallone G, et al. Transcatheter valve replacement in Asia Pacific: current practice and perspectives. J Am Coll Cardiol, 2018, 72(24): 3189-3199.
23. Wang S, Meng X, Luo Z, et al. Transapical beating-heart mitral valve repair using a novel artificial chordae implantation system. Ann Thorac Surg, 2018, 106(5): e265-e267.
24. Pan W, Zhou D, Wu Y, et al. First-in-human results of a novel user-friendly transcatheter edge-to-edge mitral valve repair device. JACC Cardiovasc Interv, 2019, 12(23): 2441-2443.
25. Cao P. A new, non-radial force transcatheter tricuspid valve replacement (LuX Medical). (2019-09-26)[2020-04-16]. https://www.tctmd.com/slide/new-non-radial-force-transcatheter-tricuspid-valve-replacement-lux-medical.

West China Medical Journal

Progress of transcatheter heart valve intervention

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content